
Seattle biotech startup Accipiter Bio has raised an additional $10.5 million from existing investors to accelerate its work on AI-designed, multi-target protein therapeutics. Fueled by faster-than-expected progress, the company plans to use the new capital to expand its team and double its roster of clinical-stage drug candidates, with a growing focus on immunology. Read More
Vollständiger Original-Bericht
Ausführliche Details, Code-Beispiele & Hersteller-Stellungnahme auf geekwire.com.
SOCIAL SHARE CARD GENERATOR